The lawsuit, filed recently in the United States District Court for the District of Delaware, asserts that Stimwave is infringing Nevro’s patents covering inventions relating to Nevro’s Senza system and HF10 therapy. The lawsuit seeks preliminary and permanent injunctive relief against further infringement as well as damages and attorney’s fees.
“Nevro was founded in 2006 to develop meaningful advances in the treatment of chronic pain to improve patients’ lives,” says Rami Elghandour, president and CEO of Nevro, in a media release.
“Intellectual property is the basis for innovation in health sciences given the long development timelines, investment, and risk required to bring meaningful advances to market. We are committed to ensuring continued innovation in health sciences by protecting our intellectual property.”
[Source(s): Nevro Corp, PR Newswire]